Pertuzumab และ Trastuzumab ในมะเร็งเต้านม HER2-Positive ระยะเริ่มเป็น

trastuzumab  Trastuzumab deruxtecan Trastuzumab deruxtecan, sold under the brand name Enhertu, is an antibody-drug conjugate consisting of the humanized monoclonal On April 5, 2024, the Food and Drug Administration granted accelerated approval to fam-trastuzumab deruxtecan-nxki (Enhertu, Daiichi Sankyo,

The story of trastuzumab begins with Axel Ullrich's dedication to the concept that receptor tyrosine kinases must be the key to many human Cardiotoxicity Trastuzumab is a monoclonal antibody tyrosine kinase inhibitor that targets the HER2 receptor often over overexpressed or overactive in breast

Trastuzumab is a monoclonal antibody targeted against the HER2 tyrosine kinase receptor The majority of patients with metastatic breast For women with HER2-positive metastatic breast cancer, trastuzumab may be given on its own or with other treatments Treatment with trastuzumab